These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22507895)

  • 41. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
    BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The joint impact of smoking plus alcohol drinking on treatment of pulmonary tuberculosis.
    Ma Y; Che NY; Liu YH; Shu W; Du J; Xie SH; Li L
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):651-657. PubMed ID: 30771122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014].
    Wang JJ; Zhou ML; Chen C; Wu G; Zuo YP; Ren X; Chen Z; Wang WH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1409-1413. PubMed ID: 31838813
    [No Abstract]   [Full Text] [Related]  

  • 45. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
    Jaber AAS; Ibrahim B
    BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
    Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
    J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study.
    Elduma AH; Mansournia MA; Foroushani AR; Ali HMH; Elegail AMA; Elsony A; Holakouie-Naieni K
    Epidemiol Health; 2019; 41():e2019014. PubMed ID: 31010280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003.
    Feja K; McNelley E; Tran CS; Burzynski J; Saiman L
    Pediatr Infect Dis J; 2008 Oct; 27(10):907-12. PubMed ID: 18756183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China.
    Xu C; Pang Y; Li R; Ruan Y; Wang L; Chen M; Zhang H
    J Infect; 2018 Apr; 76(4):348-353. PubMed ID: 29374587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
    Xu HB; Jiang RH; Li L; Xiao HP
    Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.
    Baghaei P; Tabarsi P; Dorriz D; Marjani M; Shamaei M; Pooramiri MV; Mansouri D; Farnia P; Masjedi M; Velayati A
    Am J Ther; 2011; 18(2):e29-34. PubMed ID: 20019591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment Outcomes and Adverse Events from a Standardized Multidrug-Resistant Tuberculosis Regimen in a Rural Setting in Angola.
    Aznar ML; Rando Segura A; Moreno MM; Espasa M; Sulleiro E; Bocanegra C; Gil Olivas E; Eugénio AN; Zacarias A; Katimba D; Gabriel E; Mendioroz J; López García MT; Pumarola T; Tórtola MT; Molina I
    Am J Trop Med Hyg; 2019 Sep; 101(3):502-509. PubMed ID: 31333153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study.
    Zhang Y; Wu S; Xia Y; Wang N; Zhou L; Wang J; Fang R; Sun F; Chen M; Zhan S
    Med Sci Monit; 2017 May; 23():2348-2356. PubMed ID: 28520704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensive phase treatment outcome and associated factors among patients treated for multi drug resistant tuberculosis in Ethiopia: a retrospective cohort study.
    Molie T; Teklemariam Z; Klinkenberg E; Dessie Y; Kumsa A; Mohammed H; Debebe A; Assefa D; Habte A; Bedru A; Fiseha D; Seyoum B
    BMC Infect Dis; 2019 Sep; 19(1):818. PubMed ID: 31533644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study.
    Zheng XB; Diwan VK; Zhao Q; Hu Y; Bruchfeld J; Jiang WL; Hoffner S; Xu B
    Infect Dis Poverty; 2020 Jul; 9(1):97. PubMed ID: 32682446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis.
    Tobón Á; Rueda J; Cáceres DH; Mejía GI; Zapata EM; Montes F; Ospina A; Fadul S; Paniagua L; Robledo J
    Biomedica; 2020 Dec; 40(4):616-625. PubMed ID: 33275341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru.
    Obregón G; Zevallos K; Alarcón V; Puyén ZM; Chávez Inagaki O; Mendoza-Ticona A; Alarcón-Arrascue E; Heldal E; Moore DAJ
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1350-1357. PubMed ID: 30355416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
    Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.